TGFB1 and cancer: For instance, vismodegib, sonidegib, glasdegib, or saridegib, which target the Hedgehog pathway activation in CAFs through the impairment of a 7-transmembrane protein, smoothened (SMO) receptor [246] (Figure 7), and pirfenidone, which targets the TGF-β pathway activation in CAFs, have both enhanced the effectiveness of chemotherapeutics and immunotherapies in several cancer types, including breast, ovarian, and pancreatic tumor models in vivo [246,247,248].